Population pharmacokinetic analysis of mirtazapine

European Journal of Clinical Pharmacology

Volumn 60, Issue 7, 2004, Pages 473-480

  Grasmäder, Katja ^a   Verwohlt, Petra Louise ^a   Kühn, Kai Uwe ^a   Dragicevic, Aleksandra ^b   Von Widdern, Olrik ^a   Zobel, Astrid ^a   Hiemke, Christoph ^b   Rietschel, Marcella ^a   Maier, Wolfgang ^a   Jaehde, Ulrich ^a   Rao, Marie Luise ^a  

^a UNIVERSITY OF BONN   (Germany)

^b JOHANNES GUTENBERG UNIVERSITY   (Germany)

Author keywords

CYP2D6; Mirtazapine; Population pharmacokinetics

Indexed keywords

ALCOHOL; ATENOLOL; CANDESARTAN; CARBAMAZEPINE; CITALOPRAM; CLOMIPRAMINE; CLOPIDOGREL; CYTOCHROME P450; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; DIAZEPAM; DICLOFENAC; IRBESARTAN; LOSARTAN; MEDROXYPROGESTERONE; MELOXICAM; METOPROLOL; MIRTAZAPINE; NORETHISTERONE; OMEPRAZOLE; PANTOPRAZOLE; PAROXETINE; PHENPROCOUMON; RISPERIDONE; SALMETEROL; SIMVASTATIN; UNINDEXED DRUG; ZOLPIDEM; ZOPICLONE;

ADD ON THERAPY; ADULT; AGE DISTRIBUTION; AGED; ARTICLE; BLOOD PRESSURE; BODY HEIGHT; BODY WEIGHT; CIGARETTE SMOKING; COFFEE; COMORBIDITY; CONCENTRATION (PARAMETERS); COVARIANCE; CREATININE BLOOD LEVEL; DEPRESSION; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG METABOLISM; DRUG MONITORING; ENZYME ACTIVITY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; NONLINEAR SYSTEM; PATIENT COMPLIANCE; POPULATION RESEARCH; PRIORITY JOURNAL; PULSE RATE;

ANTIDEPRESSIVE AGENTS, TRICYCLIC; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CYTOCHROME P-450 CYP2D6; DRUG INTERACTIONS; FEMALE; GENOTYPE; HUMANS; MALE; METABOLIC CLEARANCE RATE; MIANSERIN; MIDDLE AGED;

EID: 5344225623     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00228-004-0737-0     Document Type: Article

References (33)

1. Bremner JD (1995) A double-blind comparison of Org 3770, amitriptyline, and placebo in major depression. J Clin Psychiatr 56:519-525
2. Claghorn JL, Lesem MD (1995) A double-blind placebo-controlled study of mirtazapine in depressed outpatients. J Affect Disord 34:165-171
3. Smith WT, Glaudin V, Panagides J, Gilvary E (1990) Mirtazapine vs. amitriptyline vs. placebo in the treatment of major depression. Psychopharmacol Bull 26:191-196
4. Khan MC (1994) A randomised, double-blind, placebo-controlled, 5-weeks' study of mirtazapine and placebo in hospitalized patients with major depression. Eur Neuropsychopharmacol 4:145-150
5. Vartiainen H, Leinonen E (1994) Double-blind study of mirtazapine and placebo in hospitalized patients with major depression. Eur Neuropsychopharmacol 4:145-150
6. Zivkov M, de Jongh GD (1995) Mirtazapine versus amitriptyline: a 6-week randomized double-blind multicentre trial in hospitalized depressed patients. Hum Psychopharmacol 10:173-180
7. Mullin J, Lodge A, Bennie E, McCready R, Singh Batt G, Fenton G (1996) A multicentre, double-blind, amitriptyline-controlled study of mirtazapine in patients with major depression. J Psychopharmacol 10:235-240
8. Richou H, Ruimy P, Charbaut J, Delisle JP, Brunner H, Patris M (1995) A multicentre, double-blind, clomipramine-controlled efficacy and safety study of mirtazapine. Hum Psychopharmacol 10:263-271
9. Marttila M, Jääskelainen J, Järvi R, Romanov M, Miettinen E, Sorri P, Ahlfors U, Zivkov M (1995) A double-blind study comparing the efficacy and tolerability of mirtazapine and doxepin in patients with major depression. Eur Neuropsychopharmacol 6:441-446
10. Timmer CJ, Sitsen JM, Delbressine LP (2000) Clinical pharmacokinetics of mirtazapine. Clin Pharmacokinet 38:461-474
11. Timmer CJ, Lohmann AAM, Mink CPA (1995) Pharmacokinetic dose-proportionality study at steady-state of mirtazapine from Remeron® tablets. Hum Psychopharmacol 10:S97-S106
12. Kasper S, Praschak-Rieder N, Tauscher J, Wolf R (1997) A risk-benefit assessment of mirtazapine in the treatment of depression. Drug Saf 17:251-64
13. Grasmäder K, Lohmann PL, Kuss HJ, Laux G, Hiemke C, Rao ML (2003) Therapeutisches Drug-Monitoring von Anti-depressiva-therapeutischer und gesundheitsökonomischer Nutzen. Med Mol Pharm 26:162-164
14. World Health Organization (1992) International Statistical Classification of Diseases and Related Health Problems, 1989 Revision, Geneva
15. Frahnert C, Rao ML, Grasmäder K (2003) Determination of eighteen antidepressants, four antipsychotics and active metabolites in serum by liquid chromatography: a simple tool for therapeutic drug monitoring. J Chromatogr B Biomed Sci Appl 794:35-47
16. Brockmöller J, Rost KL, Gross D, Schenkel A, Roots I (1995) Phenotyping of CYP2C19 with enantiospecific HPLC-quantification of R- and S-mephenytoin and comparison with the intron4/exon5 G-> A-splice site mutation. Pharmacogenetics 5:80-88
17. de Morais SM, Wilkinson GR, Blaisdell J, Nakamura K, Meyer UA, Goldstein JA (1994) The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans. J Biol Chem 269:15419-15422
18. Broly F, Marez D, Sabbagh N, Legrand M, Millecamps S, Lo Guidice JM, Boone P, Meyer UA (1995) An efficient strategy for detection of known and new mutations of the CYP2D6 gene using single strand conformation polymorphism analysis. Pharmacogenetics 5:373-384
19. Steen VM, Andreassen OA, Daly AK, Tefre T, Borresen AL, Idle JR, Gulbrandsen AK (1995) Detection of the poor metabolizer-associated CYP2D6(D) gene deletion allele by long-PCR technology Pharmacogenetics 5:215-223
20. Løvlie R, Daly AK, Molven A., Idle JR, Steen VM (1996) Ultrarapid metabolizers of debrisoquine: characterization and PCR-based detection of alleles with duplication of the CYP2D6 gene. FEBS Lett 392:30-34
21. WinNonMix™ Reference Guide (1999) Pharsight Cooperation, Mountain View, California
22. Franke EK, Ritschel WA (1976) Quick estimation of the absorption rate constant for clinical purposes using a nomograph. Drug Intel Clin Pharm 10:77-82
23. Voortman G, Paanakker JE (1995) Bioavailability of mirtazapine from Remeron® tablets after single and multiple oral dosing. Hum Psychopharmacol 10[Suppl]:83-96
24. Mandema JW, Verotta D, Sheiner LB (1992) Building population pharmacokinetic-pharmacodynamic models. I. Models for covariate effects. J Pharmacokinet Biopharm. 20:511-528
25. Griese EU, Zanger UM, Brudermanns U, Gaedigk A, Mikus G, Mörike K, Stuven T, Eichelbaum M (1998) Assessment of the predictive power of genotypes for the in-vivo catalytic function of CYP2D6 in a German population. Pharmacogenetics 8:15-26
26. Taube J, Halsall D, Baglin T (2000) Influence of cytochrome P-450 CYP2C9 polymorphisms on warfarin sensitivity and risk of over-anticoagulation in patients on long-term treatment. Blood 96:1816-1819
27. Xie HG, Stein CM, Wilkinson GR, Flockhart DA, Wood AJ (1999) Allelic, genotypic and phenotypic distributions of S-mephenytoin 4′-hydroxylase (CYP2C19) in healthy Caucasian populations of European descent throughout the world. Pharmacogenetics 9:539-549
28. Timmer CJ, Paanàkker JE, van Hal HJM (1996) Pharmacokinetics of mirtazapine from orally administered tablets: influence of gender, age and treatment regimen. Hum Psychopharmacol 11:497-509
29. Delbressine LPC, Moonen MEG, Kaspersen FM, Wagenaars GN, Jacobs PL, Timmer CJ, Paanakker JE, van Hal HJM, Voortman G (1998) Pharmacokinetics and biotransformation of mirtazapine in healthy volunteers. Clin Drug Invest 15:45-55
30. Stornier E, von Moltke LL, Shader RI, Greenblatt DJ (2000) Metabolism of the antidepressant mirtazapine in vitro: contribution of cytochromes P-450 1A2, 2D6 and 3A4. Drug Metab Dispos 28:1168-1175
31. Raimundo S, Fischer J, Eichelbaum M, Griese EU, Schwab M, Zanger UM (2000) Elucidation of the genetic basis of the common 'intermediate metabolizer' phenotype for drug oxidation by CYP2D6. Pharmacogenetics 10:577-581
32. Dahl ML, Voortman G, Aim C, Elwin CE, Delbressine L, Vos R, Bogaards JJP, Bertilson L (1997) In vitro and in vivo studies on the disposition of mirtazapine in humans. Clin Drug Invest 13:37-46
33. Anttila SAK, Rasanen I, Leinonen EVJ (2001) Fluvoxamine augmentation increases serum mirtazapine concentrations three- to fourfold. Ann Pharmacother 35:1221-1223